Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations

[Display omitted] Therapeutic proteins suffer from physical and chemical instability in aqueous solution. Polysorbates and poloxamers are often added for protection against interfacial stress to prevent protein aggregation and particle formation. Previous studies have revealed that the hydrolysis an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutics and biopharmaceutics 2024-11, Vol.204, p.114514, Article 114514
Hauptverfasser: Papadopoulos, Eleni, Arrahmani, Betharie Cendera, Beck, Katharina, Friess, Wolfgang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 114514
container_title European journal of pharmaceutics and biopharmaceutics
container_volume 204
creator Papadopoulos, Eleni
Arrahmani, Betharie Cendera
Beck, Katharina
Friess, Wolfgang
description [Display omitted] Therapeutic proteins suffer from physical and chemical instability in aqueous solution. Polysorbates and poloxamers are often added for protection against interfacial stress to prevent protein aggregation and particle formation. Previous studies have revealed that the hydrolysis and oxidation of polysorbates in parenteral formulations can lead to the formation of free fatty acid particles, insufficient long-term stabilization, and protein oxidation. Poloxamers, on the other hand, are considered to be less effective against protein aggregation. Here we investigated two lyso-phosphatidylcholines (LPCs) as potential alternative surfactants for protein formulations, focusing on their physicochemical behavior and their ability to protect against the formation of monoclonal antibody particles during mechanical stress. The hemolytic activity of LPC was tested in varying ratios of plasma and buffer mixtures. LPC effectively stabilized mAb formulations when shaken at concentrations several orders of magnitude below the onset of hemolysis, indicating that the potential for erythrocyte damage by LPC is non-critical. LPC formulations subjected to mechanical stress through peristaltic pumping exhibited comparable protein particle formation to those containing polysorbate 80 or poloxamer 188. Profile analysis tensiometry and dilatational rheology indicated that the stabilizing effect likely arises from the formation of a viscoelastic film at approximately the CMC. Data gathered from concentration-gradient multi-angle light scattering and isothermal titration calorimetry support this finding. Surfactant desorption was evaluated through sub-phase exchange experiments. While LPCs readily desorbed from the interface, resorption occurred rapidly enough in the bulk solution to prevent protein adsorption. Overall, LPCs behave similarly to polysorbate with respect to interfacial stabilization and show promise as a potential substitute for polysorbate in parenteral protein formulations.
doi_str_mv 10.1016/j.ejpb.2024.114514
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3110729539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641124003400</els_id><sourcerecordid>3110729539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-eaaf7da55208a5c25fc152ab5d72fd0b98fe6e1b6e1a18c548a9fb1d706bf4cf3</originalsourceid><addsrcrecordid>eNp9kEGL2zAQhUXp0s1m-wd6KD724lQjS7ENvZSl7RYCvXTPYiSNiIJsuZJTSH_92mTbYw_DDLw3D97H2DvgO-Cw_3ja0WkyO8GF3AFIBfIV20DXNnUjJbxmG943fb2XALfsrpQT51y2qnvDbpu-aUQr1YbR4VJSPR1TmY44B3eJ9phiGKnCUuFYhXGm7NEGjFWZ0YQY_lCufMrVhJlWdVGGNCYb07icOM7BJHdZLcM5LplpLPfsxmMs9PZlb9nT1y8_Hx7rw49v3x8-H2orOphrQvStQ6UE71BZobwFJdAo1wrvuOk7T3sCswxCZ5XssPcGXMv3xkvrmy37cM2dcvp1pjLrIRRLMeJI6Vx0A8Bb0aul_5aJq9XmVEomr6ccBswXDVyvePVJr3j1ildf8S5P71_yz2Yg9-_lL8_F8OlqoKXl70BZFxtotORCJjtrl8L_8p8B8dCPHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110729539</pqid></control><display><type>article</type><title>Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations</title><source>Access via ScienceDirect (Elsevier)</source><creator>Papadopoulos, Eleni ; Arrahmani, Betharie Cendera ; Beck, Katharina ; Friess, Wolfgang</creator><creatorcontrib>Papadopoulos, Eleni ; Arrahmani, Betharie Cendera ; Beck, Katharina ; Friess, Wolfgang</creatorcontrib><description>[Display omitted] Therapeutic proteins suffer from physical and chemical instability in aqueous solution. Polysorbates and poloxamers are often added for protection against interfacial stress to prevent protein aggregation and particle formation. Previous studies have revealed that the hydrolysis and oxidation of polysorbates in parenteral formulations can lead to the formation of free fatty acid particles, insufficient long-term stabilization, and protein oxidation. Poloxamers, on the other hand, are considered to be less effective against protein aggregation. Here we investigated two lyso-phosphatidylcholines (LPCs) as potential alternative surfactants for protein formulations, focusing on their physicochemical behavior and their ability to protect against the formation of monoclonal antibody particles during mechanical stress. The hemolytic activity of LPC was tested in varying ratios of plasma and buffer mixtures. LPC effectively stabilized mAb formulations when shaken at concentrations several orders of magnitude below the onset of hemolysis, indicating that the potential for erythrocyte damage by LPC is non-critical. LPC formulations subjected to mechanical stress through peristaltic pumping exhibited comparable protein particle formation to those containing polysorbate 80 or poloxamer 188. Profile analysis tensiometry and dilatational rheology indicated that the stabilizing effect likely arises from the formation of a viscoelastic film at approximately the CMC. Data gathered from concentration-gradient multi-angle light scattering and isothermal titration calorimetry support this finding. Surfactant desorption was evaluated through sub-phase exchange experiments. While LPCs readily desorbed from the interface, resorption occurred rapidly enough in the bulk solution to prevent protein adsorption. Overall, LPCs behave similarly to polysorbate with respect to interfacial stabilization and show promise as a potential substitute for polysorbate in parenteral protein formulations.</description><identifier>ISSN: 0939-6411</identifier><identifier>ISSN: 1873-3441</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2024.114514</identifier><identifier>PMID: 39332745</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Excipients ; Liquid-air interface ; Lyso-phosphatidylcholine ; Parenteral formulations ; Particle formation ; Polysorbate degradation ; Protein aggregation ; Protein stabilization ; Therapeutic Proteins</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2024-11, Vol.204, p.114514, Article 114514</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c281t-eaaf7da55208a5c25fc152ab5d72fd0b98fe6e1b6e1a18c548a9fb1d706bf4cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejpb.2024.114514$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39332745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papadopoulos, Eleni</creatorcontrib><creatorcontrib>Arrahmani, Betharie Cendera</creatorcontrib><creatorcontrib>Beck, Katharina</creatorcontrib><creatorcontrib>Friess, Wolfgang</creatorcontrib><title>Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted] Therapeutic proteins suffer from physical and chemical instability in aqueous solution. Polysorbates and poloxamers are often added for protection against interfacial stress to prevent protein aggregation and particle formation. Previous studies have revealed that the hydrolysis and oxidation of polysorbates in parenteral formulations can lead to the formation of free fatty acid particles, insufficient long-term stabilization, and protein oxidation. Poloxamers, on the other hand, are considered to be less effective against protein aggregation. Here we investigated two lyso-phosphatidylcholines (LPCs) as potential alternative surfactants for protein formulations, focusing on their physicochemical behavior and their ability to protect against the formation of monoclonal antibody particles during mechanical stress. The hemolytic activity of LPC was tested in varying ratios of plasma and buffer mixtures. LPC effectively stabilized mAb formulations when shaken at concentrations several orders of magnitude below the onset of hemolysis, indicating that the potential for erythrocyte damage by LPC is non-critical. LPC formulations subjected to mechanical stress through peristaltic pumping exhibited comparable protein particle formation to those containing polysorbate 80 or poloxamer 188. Profile analysis tensiometry and dilatational rheology indicated that the stabilizing effect likely arises from the formation of a viscoelastic film at approximately the CMC. Data gathered from concentration-gradient multi-angle light scattering and isothermal titration calorimetry support this finding. Surfactant desorption was evaluated through sub-phase exchange experiments. While LPCs readily desorbed from the interface, resorption occurred rapidly enough in the bulk solution to prevent protein adsorption. Overall, LPCs behave similarly to polysorbate with respect to interfacial stabilization and show promise as a potential substitute for polysorbate in parenteral protein formulations.</description><subject>Excipients</subject><subject>Liquid-air interface</subject><subject>Lyso-phosphatidylcholine</subject><subject>Parenteral formulations</subject><subject>Particle formation</subject><subject>Polysorbate degradation</subject><subject>Protein aggregation</subject><subject>Protein stabilization</subject><subject>Therapeutic Proteins</subject><issn>0939-6411</issn><issn>1873-3441</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEGL2zAQhUXp0s1m-wd6KD724lQjS7ENvZSl7RYCvXTPYiSNiIJsuZJTSH_92mTbYw_DDLw3D97H2DvgO-Cw_3ja0WkyO8GF3AFIBfIV20DXNnUjJbxmG943fb2XALfsrpQT51y2qnvDbpu-aUQr1YbR4VJSPR1TmY44B3eJ9phiGKnCUuFYhXGm7NEGjFWZ0YQY_lCufMrVhJlWdVGGNCYb07icOM7BJHdZLcM5LplpLPfsxmMs9PZlb9nT1y8_Hx7rw49v3x8-H2orOphrQvStQ6UE71BZobwFJdAo1wrvuOk7T3sCswxCZ5XssPcGXMv3xkvrmy37cM2dcvp1pjLrIRRLMeJI6Vx0A8Bb0aul_5aJq9XmVEomr6ccBswXDVyvePVJr3j1ildf8S5P71_yz2Yg9-_lL8_F8OlqoKXl70BZFxtotORCJjtrl8L_8p8B8dCPHg</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Papadopoulos, Eleni</creator><creator>Arrahmani, Betharie Cendera</creator><creator>Beck, Katharina</creator><creator>Friess, Wolfgang</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241101</creationdate><title>Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations</title><author>Papadopoulos, Eleni ; Arrahmani, Betharie Cendera ; Beck, Katharina ; Friess, Wolfgang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-eaaf7da55208a5c25fc152ab5d72fd0b98fe6e1b6e1a18c548a9fb1d706bf4cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Excipients</topic><topic>Liquid-air interface</topic><topic>Lyso-phosphatidylcholine</topic><topic>Parenteral formulations</topic><topic>Particle formation</topic><topic>Polysorbate degradation</topic><topic>Protein aggregation</topic><topic>Protein stabilization</topic><topic>Therapeutic Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papadopoulos, Eleni</creatorcontrib><creatorcontrib>Arrahmani, Betharie Cendera</creatorcontrib><creatorcontrib>Beck, Katharina</creatorcontrib><creatorcontrib>Friess, Wolfgang</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papadopoulos, Eleni</au><au>Arrahmani, Betharie Cendera</au><au>Beck, Katharina</au><au>Friess, Wolfgang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>204</volume><spage>114514</spage><pages>114514-</pages><artnum>114514</artnum><issn>0939-6411</issn><issn>1873-3441</issn><eissn>1873-3441</eissn><abstract>[Display omitted] Therapeutic proteins suffer from physical and chemical instability in aqueous solution. Polysorbates and poloxamers are often added for protection against interfacial stress to prevent protein aggregation and particle formation. Previous studies have revealed that the hydrolysis and oxidation of polysorbates in parenteral formulations can lead to the formation of free fatty acid particles, insufficient long-term stabilization, and protein oxidation. Poloxamers, on the other hand, are considered to be less effective against protein aggregation. Here we investigated two lyso-phosphatidylcholines (LPCs) as potential alternative surfactants for protein formulations, focusing on their physicochemical behavior and their ability to protect against the formation of monoclonal antibody particles during mechanical stress. The hemolytic activity of LPC was tested in varying ratios of plasma and buffer mixtures. LPC effectively stabilized mAb formulations when shaken at concentrations several orders of magnitude below the onset of hemolysis, indicating that the potential for erythrocyte damage by LPC is non-critical. LPC formulations subjected to mechanical stress through peristaltic pumping exhibited comparable protein particle formation to those containing polysorbate 80 or poloxamer 188. Profile analysis tensiometry and dilatational rheology indicated that the stabilizing effect likely arises from the formation of a viscoelastic film at approximately the CMC. Data gathered from concentration-gradient multi-angle light scattering and isothermal titration calorimetry support this finding. Surfactant desorption was evaluated through sub-phase exchange experiments. While LPCs readily desorbed from the interface, resorption occurred rapidly enough in the bulk solution to prevent protein adsorption. Overall, LPCs behave similarly to polysorbate with respect to interfacial stabilization and show promise as a potential substitute for polysorbate in parenteral protein formulations.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39332745</pmid><doi>10.1016/j.ejpb.2024.114514</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0939-6411
ispartof European journal of pharmaceutics and biopharmaceutics, 2024-11, Vol.204, p.114514, Article 114514
issn 0939-6411
1873-3441
1873-3441
language eng
recordid cdi_proquest_miscellaneous_3110729539
source Access via ScienceDirect (Elsevier)
subjects Excipients
Liquid-air interface
Lyso-phosphatidylcholine
Parenteral formulations
Particle formation
Polysorbate degradation
Protein aggregation
Protein stabilization
Therapeutic Proteins
title Lyso-phosphatidylcholine as an interfacial stabilizer for parenteral monoclonal antibody formulations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lyso-phosphatidylcholine%20as%20an%20interfacial%20stabilizer%20for%20parenteral%20monoclonal%20antibody%20formulations&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Papadopoulos,%20Eleni&rft.date=2024-11-01&rft.volume=204&rft.spage=114514&rft.pages=114514-&rft.artnum=114514&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2024.114514&rft_dat=%3Cproquest_cross%3E3110729539%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3110729539&rft_id=info:pmid/39332745&rft_els_id=S0939641124003400&rfr_iscdi=true